Malignant fibrous histiocytoma after radiation therapy for prostate cancer: case report

Miró, Antonio; Seta, L. De; Lizza, Nicola; Léonard, Daniel; Detry, Roger

doi:10.1179/joc.1997.9.2.162

Cited by 2 publications

(2 citation statements)

References 3 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…With respect to other malignancies which were addressed by Hinnen et al [17] only, no significantly increased risk was observed in the RT group. This finding was also confirmed by other data focusing on secondary hematologic malignancies, sarcoma and malignant fibrous histiocytoma [36,37,38]. …”

Section: Discussionsupporting

confidence: 79%

Radiation-Induced Secondary Malignancy in Prostate Cancer: A Systematic Review and Meta-Analysis

et al. 2014

View full text Add to dashboard Cite

Objective: To investigate the risk of radiation-induced secondary malignancy in patients with prostate cancer. Methods: We identified 690 references from PubMed, Embase and the Cochrane Library before August 1, 2012, that reported secondary malignancy in patients with prostate cancer after receiving radiation therapy (RT), and finally four studies were included. We calculated summary estimates using random-effects meta-analysis. Results: The overall standardized incidence ratio (SIR) of secondary malignancy in patients with prostate cancer receiving RT to the general population was 1.14 (95% CI 1.04-1.32). In the subgroup analysis, no increment in radiation-induced secondary malignancy risk was detected. In terms of SIR with different follow-up intervals, there was no difference in SIR (>6 months; <5 years) (SIR = 1.19, 95% CI 0.75-1.89) and SIR (>5 years; <10 years) (SIR = 1.39, 95% CI 0.87-2.23). When the follow-up extended to >10 years, a significantly increased secondary malignancy risk was observed (SIR = 1.45, 95% CI 1.23-1.72). There is no significantly increased secondary malignancy risk in patients receiving no RT. Conclusion: RT is associated with increased secondary malignancy in patients with prostate cancer; this effect only become conspicuous more than 10 years after treatment.

show abstract

Section: Discussionsupporting

confidence: 79%

Radiation-Induced Secondary Malignancy in Prostate Cancer: A Systematic Review and Meta-Analysis

et al. 2014

View full text Add to dashboard Cite

show abstract

“…Nevertheless, some data are available on potential secondary malignancies in other sites: hematologic malignancies [12,13,35], sarcoma [1,8,10,30,38,40,45,48,50], malignant fibrous histiocytoma [33] and squamous cell carcinoma of prostate [32,34]. Within the larger trials nonconcordant increases in the risk rates for sarcoma [6,44,51], hematologic malignancies [36], urogenital cancer [22], lung cancer [6,24,36], melanoma [36,37], gastrointestinal [36] and cerebral malignancies [36] were reported.…”

Section: Other Second Malignanciesmentioning

confidence: 99%